~ Company top-ranked among 120+ submissions for QUIET-CAR project targeting cancer and autoimmune disease
WAYNE, P.A., and UTRECHT, NETHERLANDS — August 14, 2025 — NanoCell Therapeutics, Inc. (“NanoCell”), a biotechnology company developing a non-viral, DNA-based in vivo gene therapy platform, today announced it has been awarded a Eurostars Grant from the European Union (EU) through the Horizon Europe program and the Eureka Network. The grant will fund NanoCell’s QUIET-CAR project, which is focused on the development of targeted lipid nanoparticles containing novel immune-quiet DNA constructs for in vivo CAR-T therapy.
“This funding validates our innovative approach to non-viral gene therapy and will accelerate our QUIET-CAR project toward delivering safer, more accessible CAR-T treatments for patients with cancer and autoimmune disease,” said Dr. Maurits Geerlings, CEO and President of NanoCell Therapeutics. “Being selected and top ranked among over 120 submissions in Europe’s most competitive SME funding program demonstrates the transformative potential of our technology platform.”
The QUIET-CAR project is a collaboration between NanoCell and CPTx, a biotech company developing advanced medicine using AI-supported molecular design and programmable single-stranded DNA fabrication supported by gxstrands. Eurostars, part of the European Partnership on Innovative SMEs and supported by Horizon Europe, is a premier funding initiative designed to accelerate transnational innovation. With participation from 37 countries, the program rigorously selects only the most promising technological breakthroughs, evaluated by independent experts.
NanoCell acknowledges the support of Amsterdam-based Catalyze for the successful preparation of this grant.
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. The company is dedicated to pioneering transformative in-vivo cell engineering through its non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases.
Contact:
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com